Saturday 17 October 2026
Export INM’s income statement to Excel — free account
InMed Pharmaceuticals Inc.
INM Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.32
0.01
−0.75%
Follow INM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
1.43 | 0.73 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(5.39) | (1.76) | — | — | |
P/B ratio |
0.75 | 0.44 | — | — | |
Price to Tangible BV |
0.87 | 0.52 | — | — | |
EV/Sales |
(0.08) | (0.46) | — | — | |
EV/EBITDA |
0.08 | 0.46 | — | — | |
EV/Operating CF |
0.06 | 0.34 | — | — | |
EV/FCF |
0.06 | 0.34 | — | — | |
Quick Ratio |
6.25 | 4.85 | 2.35 | 1.14 | |
Current Ratio |
6.95 | 5.94 | 3.12 | 1.37 | |
Net Debt/EBITDA |
5.35 | 3.32 | 1.87 | 0.84 | |
Debt/Assets |
1.61% | 1.11% | 0.34% | 0.00% | |
Debt/Equity |
0.02 | 0.01 | 0.00 | 0.00 | |
Asset Turnover |
0.51 | 0.59 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 1.17 | 0.57 | 0.47 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
51.92% | 76.88% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
136.77% | 197.65% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.12 | 0.14 | 0.16 | 0.00 | |
Share Based Compensation of Revenue |
1.80% | 3.08% | 0.00% | 0.00% | |
Graham Net Nets |
1.04 | 1.71 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(278.42%) | (279.95%) | — | — | |
Free Cash Flow Yield |
(91.45%) | (185.95%) | — | — | |
Revenue per Share |
0.28 | 0.21 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.60) | (0.42) | (0.71) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | (0.60) | (0.42) | (0.71) | |
Cash per Share |
2.37 | 1.77 | 1.28 | 0.54 | |
Shareholders Equity per Share |
2.93 | 2.42 | 1.70 | 0.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.93 | 2.42 | 1.70 | 0.26 | |
Free Cash Flow |
(1.61) | (2.38) | (1.70) | (2.96) | |
Working Capital |
9.25 | 7.31 | 4.68 | 0.72 | |
Net Current Asset Value |
9.03 | 7.18 | 4.65 | 0.72 | |
EV/EBIT |
0.06 | 0.32 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.31 | 0.22 | — | — | |
Average Payables |
1.07 | 1.22 | 1.21 | 1.54 | |
Average Inventory |
1.06 | 1.03 | — | — | |
Average Assets |
11.91 | 9.85 | 9.21 | 9.31 | |
Average Common Equity |
9.99 | 7.88 | 6.96 | 7.25 |
Columns are period end dates